Sometimes the biggest moments at a conference happen backstage.
At the annual STAT Summit on Oct. 15-16, that kind of moment came when one of the top biopharmaceutical executives in the world met a toddler in a tuxedo.
Emma Walmsley, the departing CEO of British pharma giant GSK and a mother of four, crouched down on the floor to greet the smiling baby. The child was unique in a way he won’t ever remember: This was KJ Muldoon, the very first child saved by gene editing with a bespoke CRISPR treatment made just for him.
KJ’s curtain call came before Walmsley’s. On stage, the researchers who had engineered his treatment said they would ask the Food and Drug Administration to bring such rare treatments to far more patients. But Walmsley, during her time on stage, was still thinking about the differences between her company’s business model and the one that saved KJ from a liver transplant and perhaps from dying.
“When you see a baby like KJ come on stage and hear the story from his parents, it’s hard not to be 100% on the side of every scientist who fights for that kind of extraordinary, transformational treatment,” Walmsley said. “I think it’s incredibly important that we protect these huge leaps forward in science.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
